ライフサイエンスコーパス: severe aortic stenosis

1 HCM could not be made because of concomitant severe aortic stenosis.

2 ow Medical (DFM) system for the treatment of severe aortic stenosis.

3 ve to high- or intermediate-risk surgery for severe aortic stenosis.

4 eplacement (TAVR) in high-risk patients with severe aortic stenosis.

5 ive in high-risk or inoperable patients with severe aortic stenosis.

6 portant goals of treatment for patients with severe aortic stenosis.

7 APIEN XT transcatheter heart valve (ESV) for severe aortic stenosis.

8 stic importance of the KCCQ in patients with severe aortic stenosis.

9 and prohibitive surgical risk patients with severe aortic stenosis.

10 ely) in high-risk patients with symptomatic, severe aortic stenosis.

11 therapeutic decision making of patients with severe aortic stenosis.

12 and equilibrium MR imaging in patients with severe aortic stenosis.

13 ified patients with symptomatic low-gradient severe aortic stenosis.

14 and in patients with conventionally defined severe aortic stenosis.

15 ption for valve replacement of patients with severe aortic stenosis.

16 n (TAVI) is a novel therapy for treatment of severe aortic stenosis.

17 R) has long been the mainstay of therapy for severe aortic stenosis.

18 lantation (TAVI) for high-risk patients with severe aortic stenosis.

19 come of Ex-PHT in asymptomatic patients with severe aortic stenosis.

20 nt option for elderly women with symptomatic severe aortic stenosis.

21 ement (AVR) is the established treatment for severe aortic stenosis.

22 with a stented porcine valve in adults with severe aortic stenosis.

23 re left ventricular systolic dysfunction and severe aortic stenosis.

24 onized management of high-risk patients with severe aortic stenosis.

25 dynamic burden in patients with asymptomatic severe aortic stenosis.

26 nical outcomes in patients with asymptomatic severe aortic stenosis.

27 high-risk operable patients with symptomatic severe aortic stenosis.

28 ring exercise and hyperemia in patients with severe aortic stenosis.

29 to hemodynamic improvement in patients with severe aortic stenosis.

30 n symptomatic and asymptomatic patients with severe aortic stenosis.

31 central concept in the care of patients with severe aortic stenosis.

32 treatment option for high-risk patients with severe aortic stenosis.

33 ion for treatment of high-risk patients with severe aortic stenosis.

34 ociated with poor prognosis in patients with severe aortic stenosis.

35 than in patients with conventionally defined severe aortic stenosis (28 +/- 5 mm vs. 31 +/- 5 mm), an

36 Eight patient-specific models of severe aortic stenosis (6 tricuspid and 2 bicuspid) were

37 s undergoing TAVI, 433 (71.4%) patients with severe aortic stenosis and a preprocedural right heart c

38 r-initiated trial in high-risk patients with severe aortic stenosis and an anatomy suitable for the t

39 al aortic-valve replacement in patients with severe aortic stenosis and an increased risk of death du

40 ized 241 high-risk patients with symptomatic severe aortic stenosis and anatomy suitable for treatmen

41 Many patients with severe aortic stenosis and coexisting conditions are not

42 for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses.

43 M system in surgical high risk patients with severe aortic stenosis and complex anatomy aortic regurg

44 nts are universally present in patients with severe aortic stenosis and comprise approximately half o

45 low-ejection fraction, low-gradient (LEF-LG) severe aortic stenosis and concomitant relevant mitral r

46 A total of 125 patients with severe aortic stenosis and ejection fraction >40% schedu

47 ose monitoring of patients with asymptomatic severe aortic stenosis and help to validate current guid

48 atheter Valves) trial in which patients with severe aortic stenosis and high surgical risk were rando

49 In patients with severe aortic stenosis and high surgical risk, PPM is mo

50 ic valve replacement (AVR) for patients with severe aortic stenosis and high surgical risk.

51 R is an alternative to AVR for patients with severe aortic stenosis and high surgical risk.

52 c valve replacement (SAVR) for patients with severe aortic stenosis and high surgical risk.

53 LF is common in severe aortic stenosis and independently predicts mortal

54 is safe and well tolerated in patients with severe aortic stenosis and is associated with improvemen

55 ntravenous nitroprusside in 25 patients with severe aortic stenosis and left ventricular systolic dys

56 le alternative for patients with symptomatic severe aortic stenosis and LV dysfunction who are at hig

57 In high-risk patients with severe aortic stenosis and LV dysfunction, mortality rat

58 In severe patients with severe aortic stenosis and LV dysfunction, transaortic v

59 For patients with asymptomatic severe aortic stenosis and normal left ventricular funct

60 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ej

61 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ej

62 ess invasive treatment in many patients with severe aortic stenosis and since its introduction to the

63 te a pig model of heart failure secondary to severe aortic stenosis and to examine the relationship b

64 Patients had severe aortic stenosis and were at increased surgical ri

65 0) were considered to have medically managed severe aortic stenosis and were tracked over 5 years to

66 y hypertension (PH) frequently coexists with severe aortic stenosis, and PH severity has been shown t

67 ) and low-gradient (mean gradient <40 mm Hg) severe aortic stenosis (aortic valve area <1 cm(2)) with

68 Thirty-nine patients with asymptomatic severe aortic stenosis (aortic valve area <1 cm(2), peak

69 etrospectively identified 2017 patients with severe aortic stenosis (aortic valve area<1 cm(2), mean

70 ad a depressed ejection fraction (<or=0.35), severe aortic stenosis (aortic-valve area, <or=1 cm2), a

71 and treatment of patients with low-flow (LF) severe aortic stenosis are controversial.

72 73 +/- 7 years) with conventionally defined severe aortic stenosis area (aortic valve area </=1 cm(2

73 linical course of patients with asymptomatic severe aortic stenosis (AS) according to the new propose

74 ofiles and compare outcomes of patients with severe aortic stenosis (AS) and coronary artery disease

75 d quality-of-life outcomes for patients with severe aortic stenosis (AS) and high surgical risk treat

76 Patients with severe aortic stenosis (AS) and paradoxical low flow (PL

77 Among patients with severe aortic stenosis (AS) and preserved ejection fract

78 2-year safety and efficacy in patients with severe aortic stenosis (AS) at extreme risk of surgery t

79 In patients with severe aortic stenosis (AS) at intermediate surgical ris

80 Patients with symptomatic severe aortic stenosis (AS) benefit from aortic valve re

81 Severe aortic stenosis (AS) can manifest as exertional a

82 low-gradient (LFLG) is sometimes observed in severe aortic stenosis (AS) despite normal ejection frac

83 Low-flow (LF) severe aortic stenosis (AS) is an independent predictor

84 of coronary artery disease in patients with severe aortic stenosis (AS) is posing challenges.

85 Severe aortic stenosis (AS) most often presents with red

86 tality in moderate to severe and paradoxical severe aortic stenosis (AS) patients with preserved ejec

87 ronary artery disease (CAD) in patients with severe aortic stenosis (AS) referred for transcatheter a

88 inical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI.

89 We examined 1,154 patients with severe aortic stenosis (AS) who underwent AVR with or wi

90 Patients with severe aortic stenosis (AS) who were deemed too high ris

91 receptor 1 and 2 levels in 21 patients with severe aortic stenosis (AS), in 26 patients with 3+ to 4

92 valve replacement (AVR) among patients with severe aortic stenosis (AS), severe left ventricular (LV

93 surgical aortic valve replacement (SAVR) for severe aortic stenosis (AS).

94 urgitation (MR) is frequent in patients with severe aortic stenosis (AS).

95 chnology for the management of patients with severe aortic stenosis (AS).

96 ic valve replacement (TAVR) in patients with severe aortic stenosis (AS).

97 r (LV) systolic dysfunction in patients with severe aortic stenosis (AS).

98 safe and effective therapy for patients with severe aortic stenosis (AS).

99 ship; 2) AVC thresholds best associated with severe aortic stenosis (AS); and 3) whether, in AS with

100 easonable in asymptomatic patients with very severe aortic stenosis (AS); however, the definition of

101 Patients with severe aortic stenosis at increased risk for surgery had

102 In patients with severe aortic stenosis at increased risk for surgery, se

103 panding valve found that among patients with severe aortic stenosis at increased risk for surgery, th

104 Patients with severe aortic stenosis at increased surgical risk contin

105 In patients with severe aortic stenosis at increased surgical risk, TAVR

106 rior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, wi

107 e and effective in patients with symptomatic severe aortic stenosis at prohibitive risk for surgical

108 ssigned 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either

109 dered to be contraindicated in patients with severe aortic stenosis because of concern that they may

110 A total of 5277 patients underwent AVR for severe aortic stenosis between 1992 and 2008.

111 rgoing surgical aortic valve replacement for severe aortic stenosis between 2012 and 2014 at our inst

112 lve replacement in symptomatic patients with severe aortic stenosis, but the impact of sex on outcome

113 eas women presented more often with moderate/severe aortic stenosis compared with men.

114 Conclusions- Among inoperable patients with severe aortic stenosis, compared with standard care, TAV

115 e of particular importance for patients with severe aortic stenosis considering transcatheter aortic

116 Patients with severe aortic stenosis deemed at increased risk for surg

117 We evaluated 1023 patients with severe aortic stenosis deemed high or extreme risk for s

118 Controversy exists whether low gradient severe aortic stenosis despite preserved ejection fracti

119 Occurrence of low gradient severe aortic stenosis despite preserved ejection fracti

120 thheld from symptomatic patients with LEF-LG severe aortic stenosis even in the presence of moderate

121 In asymptomatic patients with severe aortic stenosis, guidelines recommend left ventri

122 The definition of severe aortic stenosis has classically and retrospective

123 h patients with high gradient (>/= 40 mm Hg) severe aortic stenosis (HGSAS) and moderate AS (mean gra

124 Valve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk S

125 ((R)) System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk S

126 heter heart valve (THV) for the treatment of severe aortic stenosis in patients at extreme risk for s

127 VR is a new alternative for the treatment of severe aortic stenosis in patients at high risk for surg

128 d by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo su

129 Current guidelines define severe aortic stenosis in patients with aortic valve are

130 antation is increasingly being used to treat severe aortic stenosis in patients with high operative r

131 0), patients with ECG strain (n=21) had more severe aortic stenosis, increased left ventricular mass

132 Untreated severe aortic stenosis is a progressive disease with a p

133 SAPIEN 3 in intermediate-risk patients with severe aortic stenosis is associated with low mortality,

134 catheter aortic valve replacement (TAVR) for severe aortic stenosis is growing rapidly.

135 from an asymptomatic to symptomatic state in severe aortic stenosis is often difficult to assess.

136 he pathophysiology of low flow, low gradient severe aortic stenosis (LGSAS) with preserved ejection f

137 Low-gradient severe aortic stenosis (LGSAS) with preserved ejection f

138 of aortic valve replacement in patients with severe aortic stenosis, low transvalvular gradient, and

139 Patients with severe aortic stenosis may be deemed inoperable due to t

140 Asymptomatic patients with severe aortic stenosis may subconsciously curtail their

141 going TAVI, 113 (18.7%) patients with LEF-LG severe aortic stenosis (mean gradient </=40 mm Hg, aorti

142 The optimal management of low-gradient "severe" aortic stenosis (mean gradient <40 mm Hg, indexe

143 eter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwar

144 Patients with severe aortic stenosis (n = 61) underwent cardiac magnet

145 Asymptomatic patients with severe aortic stenosis (n=105; aortic valve area <0.6 cm

146 ompared the automated 3D TEE measurements in severe aortic stenosis (n=14), dilated root without aort

147 iomyopathy (n=34; 100% with LVH), those with severe aortic stenosis (n=21; 81% with LVH), and patient

148 son, in patients with conventionally defined severe aortic stenosis, orifice area by echo was 0.72 +/

149 k for rapid progression from mild or less to severe aortic stenosis over months, highlighting their n

150 of chronic lung disease (CLD) on outcomes of severe aortic stenosis patients across all treatment mod

151 Studies of TAVR in low-flow severe aortic stenosis patients have demonstrated that T

152 Severe aortic stenosis reduces the length and quality of

153 placement (TAVR) in inoperable patients with severe aortic stenosis remain unknown.

154 sis, and treatment of patients with low-flow severe aortic stenosis remains challenging.

155 Asymptomatic patients with severe aortic stenosis require frequent monitoring of th

156 Up to 30% of patients with severe aortic stenosis (SAS; indexed aortic valve area <

157 y enrolled in the multicenter True or Pseudo-Severe Aortic Stenosis study, 126 patients with resting

158 In asymptomatic patients with severe aortic stenosis, the main determinants of Ex-PHT

159 e to randomly assign high-risk patients with severe aortic stenosis to either SAVR or TAVR with a bal

160 ves (PARTNER) trial randomized patients with severe aortic stenosis to medical management versus tran

161 NER trial randomized high-risk patients with severe aortic stenosis to TAVR or SAVR.

162 andomly assigned 699 high-risk patients with severe aortic stenosis to undergo either surgical aortic

163 andomly assigned 699 high-risk patients with severe aortic stenosis to undergo either transcatheter a

164 In high-risk patients with severe aortic stenosis, transcatheter and surgical proce

165 In patients with severe aortic stenosis, transcatheter aortic valve repla

166 ial load were measured in 2141 patients with severe aortic stenosis treated with TAVR in the PARTNER

167 of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OBSERVANT) study.

168 of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) trial is an observatio

169 among high-risk and inoperable patients with severe aortic stenosis undergoing a transcatheter aortic

170 In patients with symptomatic severe aortic stenosis undergoing aortic valve replaceme

171 werful predictor of outcome in patients with severe aortic stenosis undergoing aortic valve replaceme

172 Elderly patients with severe aortic stenosis undergoing medical management hav

173 clinical trial in higher-risk patients with severe aortic stenosis undergoing TAVI at the University

174 Among patients with severe aortic stenosis undergoing TAVI, the use of a cer

175 AF is common among high-risk patients with severe aortic stenosis undergoing transcatheter aortic v

176 edium-term mortality rates for patients with severe aortic stenosis undergoing transcatheter aortic v

177 y-four consecutive patients with inoperable, severe aortic stenosis underwent TAO TAVR in our institu

178 1 years, log EuroSCORE: 25.0 +/- 15.0%) with severe aortic stenosis underwent transfemoral TAVI at 2

179 Minnesota) was implanted in 10 patients with severe aortic stenosis utilizing percutaneous femoral ar

180 Patients undergoing AVR for severe aortic stenosis were analyzed using the Northern

181 One hundred high surgical risk patients with severe aortic stenosis were evaluated for the primary en

182 to July 2009, a cohort of 362 patients with severe aortic stenosis were screened and did not meet th

183 an or equal to III+ aortic regurgitation and severe aortic stenosis were seen in 37% and 10%, respect

184 moderate to severe aortic regurgitation, and severe aortic stenosis were seen in 7%, 18%, and 2%, whe

185 rtic sclerosis; 25 mild, 33 moderate, and 23 severe aortic stenosis) were administered both 18F-NaF a

186 fective therapy in symptomatic patients with severe aortic stenosis, whereas the management of asympt

187 ension frequently coexists with low-gradient severe aortic stenosis, which itself may cause elevated

188 acement (SAVR) for patients with symptomatic severe aortic stenosis who are at high risk of periopera

189 pted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, le

190 w method to treat patients with symptomatic, severe aortic stenosis who are at high surgical risk.

191 (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk.

192 tiveness of the Lotus valve in patients with severe aortic stenosis who are at high surgical risk.

193 In patients with severe aortic stenosis who are at increased surgical ris

194 In patients with severe aortic stenosis who are at increased surgical ris

195 od 30 day clinical outcomes in patients with severe aortic stenosis who are at intermediate risk of s

196 s currently being evaluated in patients with severe aortic stenosis who are considered high-risk surg

197 For patients with severe aortic stenosis who are not candidates for surger

198 is the recommended therapy for patients with severe aortic stenosis who are not suitable candidates f

199 ) is an accepted treatment for patients with severe aortic stenosis who are not suitable for surgery.

200 eter heart valve (THV) size in patients with severe aortic stenosis who are suboptimal surgical candi

201 In patients with severe aortic stenosis who cannot have surgery, transcat

202 pared with standard therapy in patients with severe aortic stenosis who cannot have surgery.

203 vational cohort study included patients with severe aortic stenosis who underwent TAVR in the Society

204 We recruited patients with severe aortic stenosis who were at increased surgical ri

205 Patients with severe aortic stenosis who were at increased surgical ri

206 trial randomized patients with symptomatic, severe aortic stenosis who were not candidates for surge

207 trial randomized patients with symptomatic, severe aortic stenosis who were not candidates for surgi

208 Among appropriately selected patients with severe aortic stenosis who were not suitable candidates

209 In patients with severe aortic stenosis who were not suitable candidates

210 tudy involved 300 patients with asymptomatic severe aortic stenosis who were seen in the ambulatory M

211 We randomly assigned patients with severe aortic stenosis, whom surgeons considered not to

212 3.2 million (95% CI, 2.2-4.4) patients have severe aortic stenosis with 1.9 million (95% CI, 1.3-2.6

213 We compared outcomes of low-gradient severe aortic stenosis with AVR or medical therapy.

214 unctional status in inoperable patients with severe aortic stenosis with durable hemodynamic benefit

215 the management of patients with low-gradient severe aortic stenosis with preserved ejection fraction

216 Low-gradient severe aortic stenosis with preserved ejection fraction

217 Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction

218 -expanding TAVR in patients with symptomatic severe aortic stenosis with prohibitive risks for surger

219 o undergo aortic valve replacement (AVR) for severe aortic stenosis with reduced preoperative ejectio